QQ客服 官方微博 反馈留言

	The role of weekly nanoparticle albumin bound paclitaxel monotherapy as second line or later treatment for advanced NSCLC in China
	Xing, Puyuan; Zhu, Yixiang; Shan, Ling; Chen, Sipeng; Hao, Xuezhi; Li, Junling
	2017
卷号	8期号:50页码:87442-87454
关键词	advanced non-small cell lung cancer (NSCLC) multiple treatments taxane nanoparticle albumin bound paclitaxel (Nab-PTX) secreted protein acidic and rich in cysteine (SPARC)
ISSN号	1949-2553
DOI	10.18632/oncotarget.21103
URL标识	查看原文
收录类别	SCIE ; PUBMED
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6363613
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Xing, Puyuan,Zhu, Yixiang,Shan, Ling,et al. The role of weekly nanoparticle albumin bound paclitaxel monotherapy as second line or later treatment for advanced NSCLC in China[J],2017,8(50):87442-87454.
APA	Xing, Puyuan,Zhu, Yixiang,Shan, Ling,Chen, Sipeng,Hao, Xuezhi,&Li, Junling.(2017).The role of weekly nanoparticle albumin bound paclitaxel monotherapy as second line or later treatment for advanced NSCLC in China.,8(50),87442-87454.
MLA	Xing, Puyuan,et al."The role of weekly nanoparticle albumin bound paclitaxel monotherapy as second line or later treatment for advanced NSCLC in China".8.50(2017):87442-87454.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。